Susanna Mantovani

Susanna Mantovani

Auto-generated profile, based on publicly available information

Susanna Mantovani

Dulbecco Telethon Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
RGRichard Gordon
Richard Gordon
EAEduardo A. Albornoz
Eduardo A. Albornoz
DCDaniel C. Christie
Daniel C. Christie
MLMonica R. Langley
Monica R. Langley
VKVinod Kumar
Vinod Kumar
TWTrent M. Woodruff
Trent M. Woodruff
Oral treatment with a brain-penetrant NLRP3 inhibitor has protective effects in preclinical models of Parkinson’s disease.

21 May 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MWMike C. L. Wu
Mike C. L. Wu
FBFaith H. Brennan
Faith H. Brennan
JLJason P. L. Lynch
Jason P. L. Lynch
SMSusanna Mantovani
Susanna Mantovani
SPSimon Phipps
Simon Phipps
TWTrent M. Woodruff
Trent M. Woodruff
C3a is a key complement activation fragment, yet its neutrophil-expressed receptor (C3aR) still has no clearly defined role. In this study, we used a neutrophil-dependent mouse model of intestinal ischemia-reperfusion (IR) injury to explore the role of C3aR in acute tissue injuries. C3aR deficiency worsened intestinal injury, which corresponded with increased numbers of tissue-infiltrating neutrophils. Circulating neutrophils were significantly increased in C3aR −/− mice after intestinal ischemia, and C3aR −/− mice also mobilized more circulating neutrophils after granulocyte colony-stimulating factor infusion compared with WT mice, indicating a specific role for C3aR in constraining neutrophil mobilization in response to intestinal injury. In support of this role, C3aR −/− mice reconstituted with WT bone marrow reversed IR pathology back to WT levels. Complement C5a receptor (C5aR) antagonism in C3aR −/− mice also rectified the worsened pathology after intestinal IR injury but had no effect on circulating neutrophils, highlighting the opposing roles of C3a and C5a in disease pathogenesis. Finally, we found that using a potent C3a agonist to activate C3aR in vivo reduced neutrophil mobilization and ameliorated intestinal IR pathology in WT, but not C3aR −/− , mice. This study identifies a role for C3aR in regulating neutrophil mobilization after acute intestinal injury and highlights C3aR agonism as a potential treatment option for acute, neutrophil-driven pathologies.

1 March 2018 in Journal of Sleep Research
Verified
Journal Article
Closed access
PDF file
SMSusanna Mantovani
Susanna Mantovani
SSSimon Smith
Simon Smith
RGRichard Gordon
Richard Gordon
JOJohn D. O'SUllivan
John D. O'SUllivan

1 October 2015 in Journal of the Neurological Sciences
Verified
Journal Article
Open access
Shyuan T. NgoShyuan T. Ngo
Shyuan T. Ngo
Frederik J. SteynFrederik J. Steyn
Frederik J. Steyn
LHL. Huang
L. Huang
SMS. Mantovani
S. Mantovani
CPC.M.M. Pfluger
C.M.M. Pfluger
PMPamela Ann McCombe
Pamela Ann McCombe
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease characterized by the loss of upper cortical and lower motor neurons. ALS causes death within 2-5years of diagnosis. Diet and body mass index influence the clinical course of disease, however there is limited information about the expression of metabolic proteins and fat-derived cytokines (adipokines) in ALS. In healthy controls and subjects with ALS, we have measured levels of proteins and adipokines that influence metabolism. We find altered levels of active ghrelin, gastric inhibitory peptide (GIP), pancreatic polypeptide (PP), lipocalin-2, plasminogen activator inhibitor-1 (PAI-1), interleukin-6 (IL-6) and 8 (IL-8), and tumor necrosis factor alpha (TNFα) in the plasma of ALS patients relative to controls. We also observe a positive correlation between the expression of plasma nerve growth factor (NGF) relative to disease duration, and an inverse correlation between plasma glucagon and the ALS functional rating scale-revised (ALSFRS-R). Further studies are required to determine whether altered expression of metabolic proteins and adipokines contribute to motor neuron vulnerability and how these factors act to modify the course of disease.

1 November 2014 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
SMS. Mantovani
S. Mantovani
RGR. Gordon
R. Gordon
JMJ.K. Macmaw
J.K. Macmaw
CPC.M.M. Pfluger
C.M.M. Pfluger
RHR.D. Henderson
R.D. Henderson
TWT.M. Woodruff
T.M. Woodruff

16 April 2015 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
IBIhssane Bouybayoune
Ihssane Bouybayoune
SMSusanna Mantovani
Susanna Mantovani
Federico Del GalloFederico Del Gallo
Federico Del Gallo
IBIlaria Bertani
Ilaria Bertani
Elena RestelliElena Restelli
Elena Restelli
RCRoberto Chiesa
Roberto Chiesa
Fatal familial insomnia (FFI) and a genetic form of Creutzfeldt-Jakob disease (CJD178) are clinically different prion disorders linked to the D178N prion protein (PrP) mutation. The disease phenotype is determined by the 129 M/V polymorphism on the mutant allele, which is thought to influence D178N PrP misfolding, leading to the formation of distinctive prion strains with specific neurotoxic properties. However, the mechanism by which misfolded variants of mutant PrP cause different diseases is not known. We generated transgenic (Tg) mice expressing the mouse PrP homolog of the FFI mutation. These mice synthesize a misfolded form of mutant PrP in their brains and develop a neurological illness with severe sleep disruption, highly reminiscent of FFI and different from that of analogously generated Tg(CJD) mice modeling CJD178. No prion infectivity was detectable in Tg(FFI) and Tg(CJD) brains by bioassay or protein misfolding cyclic amplification, indicating that mutant PrP has disease-encoding properties that do not depend on its ability to propagate its misfolded conformation. Tg(FFI) and Tg(CJD) neurons have different patterns of intracellular PrP accumulation associated with distinct morphological abnormalities of the endoplasmic reticulum and Golgi, suggesting that mutation-specific alterations of secretory transport may contribute to the disease phenotype. Genetic prion diseases are degenerative brain disorders caused by mutations in the gene encoding the prion protein (PrP). Different PrP mutations cause different diseases, including Creutzfeldt-Jakob disease (CJD) and fatal familial insomnia (FFI). The reason for this variability is not known, but assembly of the mutant PrPs into distinct aggregates that spread in the brain by promoting PrP aggregation may contribute to the disease phenotype. We previously generated transgenic mice modeling genetic CJD, clinically identified by dementia and motor abnormalities. We have now generated transgenic mice carrying the PrP mutation associated with FFI, and found that they develop severe sleep abnormalities and other key features of the human disorder. Thus, transgenic mice recapitulate the phenotypic differences seen in humans. The mutant PrPs in FFI and CJD mice are aggregated but unable to promote PrP aggregation. They accumulate in different intracellular compartments and cause distinct morphological abnormalities of transport organelles. These results indicate that mutant PrP has disease-encoding properties that are independent of its ability to self-propagate, and suggest that the phenotypic heterogeneity may be due to different effects of aggregated PrP on intracellular transport. Our study provides new insights into the mechanisms of selective neuronal dysfunction due to protein aggregation.